Parkinson’s Disease - Epidemiology Forecast to 2029
Parkinson's disease (PD) is a progressive disorder of the nervous system that affects movement by causing shaking, stiffness, and difficulty with walking, balance, and coordination (National Institute on Aging, 2017; Mayo Clinic, 2020). PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression (World Health Organization, 2020). PD is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, affecting 1-2% of individuals ages 65 years and older worldwide (Mhyre et al., 2012; Kowal et al., 2013).
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for PD in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex, age, and HY clinical staging.
The following data describes epidemiology of PD. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of PD from 2,434,438 cases in 2019 to 2,999,337 cases in 2029, at an AGR of 2.32% over the forecast period. Men accounted for slightly more diagnosed prevalent cases of PD than women in the 7MM, and is one of the most common chronic progressive neurodegenerative disorders in the elderly population, as PD predominantly affects older adults. These trends are reflected in GlobalData’s forecast for the diagnosed prevalent cases for the 7MM.
Reasons to Buy
- The Parkinson’s Disease (PD) Epidemiology Report and Model provide an overview of the risk factors and global trends of PD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of PD are further segmented by Hoehn and Yahr (HY) clinical staging (stages I, II, III, IV, and V), and grouped into early (equivalent to HY clinical stages I-II), moderate-advanced (equivalent to HY clinical stages III-V), and advanced (equivalent to HY clinical stages IV-V).
- The PD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
The Parkinson’s Disease Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global PD market.
- Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD therapeutics in each of the markets covered.
- Understand magnitude of PD population by clinical staging.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Parkinson’s Disease: Executive Summary
- 2.1 Catalyst
- 2.2 Related Reports
- 2.3 Upcoming Reports
- 3 Epidemiology
- 3.1 Disease Background
- 3.2 Risk Factors and Comorbidities
- 3.3 Global and Historical Trends
- 3.4 Forecast Methodology
- 3.4.1 Sources
- 3.4.2 Forecast Assumptions and Methods
- 3.5 Epidemiological Forecast for PD (2019-2029)
- 3.5.1 Diagnosed Prevalent Cases of PD
- 3.5.2 Sex-Specific Diagnosed Prevalent Cases of PD
- 3.5.3 Age-Specific Diagnosed Prevalent Cases of PD
- 3.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging
- 3.5.5 Diagnosed Prevalent Cases of PD by Type
- 3.6 Discussion
- 3.6.1 Epidemiological Forecast Insight
- 3.6.2 COVID-19 Impact
- 3.6.3 Limitations of the Analysis
- 3.6.4 Strengths of the Analysis
- 4 Appendix
- 4.1 Bibliography
- 4.2 About the Authors
- 4.2.1 Epidemiologist
- 4.2.2 Reviewers
- 4.2.3 Global Director of Therapy Analysis and Epidemiology
- 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
- 4.3 About GlobalData
- 4.4 Contact Us
- 4.5 Disclaimer
- List of Tables
- Table 1: Summary of Newly Added Data Types
- Table 2: Summary of Updated Data Types
- Table 3: Risk Factors and Comorbidities of PD
- List of Figures
- Figure 1: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
- Figure 2: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019
- Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
- Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
- Figure 5: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019
- Figure 6: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019
- Figure 7: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
- Figure 8: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019
- Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019